Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by enhancing anti-tumor immune responses, yet their use can lead to immune-related adverse events (irAE), including neurological complications. Despite their clinical relevance, predictive biomarkers for irAE remain scarce, and ea...

Full description

Saved in:
Bibliographic Details
Main Authors: Nora Möhn, Emily Narten, Laura Duzzi, Janin Thomas, Lea Grote-Levi, Gernot Beutel, Tabea Fröhlich, Benjamin-Alexander Bollmann, Thomas Wirth, Imke von Wasielewski, Ralf Gutzmer, Florian Heidel, Frank Pessler, Walter Zobl, Sven Schuchardt, Philipp Ivanyi, Sandra Nay, Thomas Skripuletz
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Checkpoint inhibitors
immune-related adverse events
neurotoxicity
biomarker
metabolomics
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2547271
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items